Skip to content
OpenCapital
Get started

ResMed RMD Residential Care Software — R&D

Other segment segments

Sleep And Breathing Health
$56.41M+19.4%

Similar metrics at other companies

Progress Software logo
PRGSResearch and Development Expense, Software (Excluding Acquired in Process Cost)
$48.84M+4.9%
ACI Worldwide logo
ACIWResearch and Development Expense, Software (Excluding Acquired in Process Cost)
$44.09M+13.3%
CoStar Group logo
CSGPResearch and Development Expense, Software (Excluding Acquired in Process Cost)
$114M+20.0%
Gloo Holdings, Inc. logo
GLOOResearch and Development Expense, Software (Excluding Acquired in Process Cost)
$3.9M-31.8%
Comstock Inc. logo
LODEResearch And Development Expense Paid For Software
$763.22K-75.1%
MVB Financial Corp. logo
MVBFResearch and Development Expense, Software (Excluding Acquired in Process Cost)
$1.42M+102%

Other financials

Income statement

See full
Revenue$1.4B+10.8%
Gross profit$891.0M+16.3%
Operating income$499.8M+17.3%
Net income$398.7M+9.2%
EPS (diluted)$2.74+10.5%

Balance sheet

See full
Cash & equivalents$1.7B+78.0%
Total debt$1.1B+29.8%
Total equity$6.5B+17.1%
Total assets$8.8B+16.1%

Cash flow

See full
Operating cash flow$554.1M-4.2%
CapEx$33.7M+61.8%
Free cash flow$520.5M-6.7%

Valuation

See full
Market cap$29.05B-22.6%
Enterprise value$28.5B-23.3%
P/E19.1×-7.7×
P/S5.3×-2.0×

Profitability

See full
Gross margin61.6%+2.8pp
Operating margin34.2%+2.1pp
Net margin27.4%+1.3pp
FCF margin31.7%+0.4pp

Returns & leverage

See full
Return on equity25.2%-0.6pp
Debt / equity0.2×0.0×
Current ratio3×-0.4×

Where this comes from

Reported directly by ResMed in its filing.

Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.

The official record: ResMed’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about ResMed's residential care software — r&d.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is ResMed's residential care software — R&D?
ResMed (RMD) reported residential care software — R&D of $26.23M in Q1 2026.
How has ResMed's residential care software — R&D changed year-over-year?
ResMed's residential care software — R&D increased by 5.3% year-over-year, from $24.92M to $26.23M.
What is the long-term trend for ResMed's residential care software — R&D?
Over 2 years (2023 to 2025), ResMed's residential care software — R&D has grown at a 6.0% compound annual growth rate (CAGR), from $87.12M to $97.96M.
What does residential care software — R&D mean?
Captures the investment in engineering, software development, and product innovation specifically for the residential care software portfolio. This reflects the company's commitment to enhancing platform features and maintaining a competitive technological edge.